New ADHD pill aims to control symptoms for 16 hours

NCT ID NCT05631626

Completed Disease control Sponsor: Cingulate Therapeutics Source: ClinicalTrials.gov ↗

First seen Jul 02, 2026 · Last updated Jul 02, 2026

Summary

This phase 3 trial tests whether a new formulation of dexmethylphenidate (CTx-1301) can improve attention and reduce ADHD symptoms in adults for up to 16 hours. Participants take an optimized dose (25, 37.5, or 50 mg) and complete math tests in a simulated classroom. The study compares the drug's effects against a placebo to see if it offers longer-lasting symptom control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CTx-1301 (dexmethylphenidate)
What this could lead to: If successful, this could provide a longer-lasting, once-daily treatment option for adults with ADHD, improving attention and symptom control throughout the day.
What could go wrong: This is a small, single-center trial. The drug may not show significant benefit over placebo, and side effects common to stimulants (e.g., insomnia, appetite loss) may occur.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADHD are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

attention deficit hyperactivity disorder, inattentive type attention deficit-hyperactivity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADHD ADHD - COMBINED TYPE ATTENTION DEFICIT HYPERACTIVITY DISORDER ATTENTION DEFICIT HYPERACTIVITY DISORDER COMBINED

Contacts and locations

Locations

Clinical Research of Southern Nevada, LLC

Las Vegas, Nevada, 89128, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.